Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6912925 | 0.77 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL6917336 | 0.76 | CHRM1 (1.00) | CHRM1CHRM2CHRM3MAOA | |
| SCHEMBL6915153 | 0.75 | CHRM1 (0.60) | CHRM1 | |
| SCHEMBL8076754 | 0.74 | CHRM1 (0.85) | CHRM1KCNH2 | |
| SCHEMBL6907680 | 0.74 | CHRM1 (0.62) | CHRM1 | |
| SCHEMBL6911863 | 0.73 | CHRNB2 (0.55) | CHRM1 | |
| SCHEMBL31112842 | 0.72 | CHRM1 (0.49) | CHRM1CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL14886385 | 0.71 | LIPC (0.39) | — | |
| SCHEMBL14886377 | 0.71 | LIPC (0.39) | — | |
| SCHEMBL12204126 | 0.71 | LIPC (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2000501384-A | — | — | 2000-02-08 | — | — | JP | claimed |
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | claimed |
| EP-0874828-A4 | COMPOSITION FOR TREATING PAIN | LILLY CO ELI (US) | 1999-09-01 | — | — | EP | claimed |
| EP-0874828-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | claimed |
| US-5665745-A | 1,2,5-THIADIAZOLE DERIVATIVES FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | claimed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | claimed |
| WO-1997017962-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | claimed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | claimed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| US-20040023951-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY | 2004-02-05 | — | — | US | disclosed |
| EP-1316203-A2 | COMBINATION FOR TREATING PSYCHOSES, COMPRISING AN ANTIPSYCHOTIC AND A MUSCARINIC AGONIST | ELI LILLY AND COMPANY (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002003684-A2 | COMBINATION FOR TREATING PSYCHOSES, COMPRISING AN ANTIPSYCHOTIC AND A MUSCARINIC AGONIST | ELI LILLY AND COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0874828-A4 | COMPOSITION FOR TREATING PAIN | LILLY CO ELI (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5665745-A | 1,2,5-THIADIAZOLE DERIVATIVES FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| US-5646289-A | REACTING A 3-CHLORO-1,2,5-THIADIAZOLE WITH ALKALI METAL BIS(TRIALKYL OR ARYLSILYL)AMIDE; DECHLORINATION; TREATING NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997017962-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023951-A1 | Combination therapy for treatment of psychoses | CHRM5, CHRM4, CHRM2 | CHRM1 8/4885CHRM2 3/4885CHRM4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.